EP3463328
Seladelpar til að meðhöndla frumlæga gallskorpulifur
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
26.4.2017EP published:
15.6.2022EP application number:
17722943.2
EP translation filed:
23.6.2022Grant published:
15.7.2022EPO information:
European Patent Register
Max expiry date:
25.4.2037Expiry date:
25.4.2026Next due date:
30.4.2026
Title in English:
SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITISLanguage of the patent:
English
Timeline
Today
26.4.2017EP application
15.6.2022EP Publication
23.6.2022Translation submitted
15.7.2022Registration published
25.4.2026Expires
Owner
Name:
CymaBay Therapeutics, Inc.Address:
7575 Gateway Boulevard, Suite 110, Newark, CA 94560, US
Inventor
Name:
BOUDES, PolAddress:
Newark, CA 94560, US
Name:
MCWHERTER, Charles, A.Address:
Newark, CA 94560, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201662343688 PDate:
31.5.2016Country:
US
Classification
Categories:
A61K 31/192, A61P 1/16
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 8.3.2023
Expires: 25.4.2024
Payer: Árnason Faktor ehf.
Number: 8
Paid: 7.3.2024
Expires: 25.4.2025
Payer: Árnason Faktor ehf.
Number: 9
Paid: 18.3.2025
Expires: 25.4.2026
Payer: Árnason Faktor ehf.